| MADRIGAL PHARMACEUTICALS |
| USA |
| Gesundheit |
| US5588681057 / A2APCZ |
| YDO1 (Frankfurt) / MDGL (NASDAQ) |
| FRA:YDO1, ETR:YDO1, YDO1:GR, NASDAQ:MDGL |
| - |
| https://www.madrigalpharm.. |
|
Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead produ..
>Volltext.. |
| 8909.26 Mio. EUR |
| 8478.59 Mio. EUR |
| 1150.44 Mio. EUR |
| -287.71 Mio. EUR |
| -291.29 Mio. EUR |
| -11.54 EUR |
| 311.59 Mio. EUR |
| 262.43 Mio. EUR |
| -177.16 Mio. EUR |
| 2.24 |
| 156.88% |
| -18.95% |
| - |
| - |
| - |
| - |
| MADRIGAL |
| 03.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|